Picture of Gubra A/S logo

GUBRA Gubra A/S Share Price

0.000.00%
dk flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Momentum

Relative Strength (%)
1m-2.34%
3m+121.8%
6m+137.23%
1yr+143.26%
Volume Change (%)
10d/3m-47.88%
Price vs... (%)
52w High-18.5%
50d MA+13.48%
200d MA+92.65%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-8.81%
Return on Equity-15.15%
Operating Margin-23.25%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Gubra A/S EPS forecast chart

Profile Summary

Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    October 9th, 2008
    Public Since
    April 4th, 2023
    No. of Employees
    219
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    dk flag iconOMX Nordic Exchange - Copenhagen
    Shares in Issue
    16,290,432
    Blurred out image of a map
    Address
    Hoersholm Kongevej 11 B, HOERSHOLM, 2970
    Web
    https://www.gubra.dk/
    Phone
    Contact
    Kristian Borbos
    Auditors
    PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELS

    GUBRA Share Price Performance

    Similar to GUBRA

    Picture of Genmab A/S logo

    Genmab A/S

    dk flag iconOMX Nordic Exchange - Copenhagen

    Picture of Orphazyme A/S logo

    Orphazyme A/S

    dk flag iconOMX Nordic Exchange - Copenhagen

    Picture of ViroGates A/S logo

    ViroGates A/S

    dk flag iconOMX Nordic Exchange - Copenhagen

    Picture of Zealand Pharma A/S logo

    Zealand Pharma A/S

    dk flag iconOMX Nordic Exchange - Copenhagen

    FAQ